comparemela.com

Latest Breaking News On - பாஸ்கல் நீகெண் - Page 5 : comparemela.com

Tetra Bio-Pharma Creates the ENJOUCA Business Unit

Tetra Bio-Pharma Creates the ENJOUCA Business Unit OTTAWA, ON / ACCESSWIRE / February 3, 2021 / Tetra Bio-Pharma Inc. ( Tetra or the Company ) (TSX:TBP)(OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announced today the creation of a wholly-owned subsidiary called ENJOUCA. Jurisdictions differ greatly in terms of regulatory requirements surrounding medical cannabis, which means that in some territories, QIXLEEF can be commercialized as a medical cannabis product. As a result, Tetra s strategy is to launch QIXLEEF under the trademark, ENJOUCA as a medical cannabis product within those territories using its robust clinical package. ENJOUCA branded products will be distributed through existing medical cannabis channels.

Tetra Bio-Pharma Announces FDA Clearance on IND, allowing U S Reborn1 Clinical Trial to Commence

Tetra Bio-Pharma Announces FDA Clearance on IND, allowing U.S. Reborn1 Clinical Trial to Commence OTTAWA, ON / ACCESSWIRE / January 29, 2021 / Tetra Bio-Pharma Inc. ( Tetra or the Company ) (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company s Investigational New Drug (IND) application, allowing Tetra to initiate its QIXLEEF TM Reborn1 TM clinical trial in cancer patients with breakthrough pain. This is really good news for all of us and in particular for the cancer patients that suffer from breakthrough pain. We aim to initiate this proof-of-concept trial designed to demonstrate that QIXLEEF

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.